SF3A3 in Liver Hepatocellular Carcinoma: Oncogenic Role and Prognostic Significance [0.03%]
肝癌中SF3A3的致癌作用及其预后意义研究
Fangran Liu,Paul David Blakeley
Fangran Liu
Background: Splicing factor 3a subunit 3 (SF3A3) is a core component of the SF3A complex, which is essential for pre‑mRNA splicing. However, its role and prognostic significance in liver hepatocellular carcinoma (LIHC) r...
Letter to the Editor [0.03%]
致编辑的信
Alfonso Duenas-Gonzalez
Alfonso Duenas-Gonzalez
FLAG-Based Versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis [0.03%]
基于标志物的诱导治疗与标准化疗（阿糖胞苷和 idarubicin）在新诊断急性髓系白血病成人患者中的疗效比较：系统评价和 meta 分析
Mohammed Abdulgayoom,Soha Aboukhalaf,Mahmoud Osman et al.
Mohammed Abdulgayoom et al.
The standard induction regimen for newly diagnosed acute myeloid leukemia (AML) in eligible patients remains cytarabine-daunorubicin (7+3), although FLAG-based regimens are increasingly used in high-risk disease. We performed a PRISMA 2020-...
Longitudinal Changes in Body Weight and Body Mass Index in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Retrospective Observational Study [0.03%]
酪氨酸激酶抑制剂治疗慢性期慢性髓性白血病患者体重及体质指数纵向变化的回顾性研究
Awni Alshurafa,Mohammed Abdulgayoom,Rola Ghasoub et al.
Awni Alshurafa et al.
Background: Tyrosine kinase inhibitors (TKIs) have transformed chronic-phase chronic myeloid leukemia (CML) into a chronic condition with excellent long-term survival. As outcomes improve, attention has shifted toward tre...
Rising lung cancer burden attributable to high fasting plasma glucose in women aged ≥50 years: age-, SDI-, and BRICS-specific patterns from GBD 1990-2021 [0.03%]
基于GBD 1990-2021：≥50岁女性空腹血糖水平升高所致肺癌负担加剧：按年龄、SDI和金砖国家分列的模式
Lili Lin,Xiaoqin Huang,Bijun Li et al.
Lili Lin et al.
Background: We quantified trends and heterogeneity in lung cancer burden attributable to high fasting plasma glucose (HFPG) among women aged ≥50 years (used as a population-level proxy for postmenopausal status) globally...
Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis [0.03%]
一线阿特朱单抗联合贝伐珠单抗治疗初始诊断为不适合局部区域疗法的肝细胞癌患者的诊疗路径和结果分析
Gakushi Komura,Teiji Kuzuya,Hisanori Muto et al.
Gakushi Komura et al.
Introduction: Real-world evidence is limited for patients with unresectable hepatocellular carcinoma (HCC) who are ineligible for locoregional therapy (LRT) at initial diagnosis. We examined diagnostic pathways and outcom...
Retrospective comparison of capecitabine plus oxaliplatin and docetaxel plus S-1 as adjuvant chemotherapy for pathological stage III gastric cancer [0.03%]
卡培他滨联合奥沙利铂与多西他赛联合S-1作为III期胃癌辅助化疗的对比研究
Toru Imai,Hidekazu Hirano,Hirokazu Shoji et al.
Toru Imai et al.
Background: Adjuvant chemotherapy following surgical resection is the standard treatment for patients with pathological stage III (pStageIII) gastric cancer (GC) in Japan. Capecitabine plus oxaliplatin (CapeOX) and doceta...
Susanne Weindler,Thomas Hundsberger,Alfredo Addeo et al.
Susanne Weindler et al.
Background/objectives: Guidelines suggest intrathecal (IT) pharmacotherapy for patients with leptomeningeal disease (LMD). However, evidence on the benefit of IT treatment is limited and IT therapy is an invasive procedur...
Association between clinicopathological features and BRAF V600E mutation in papillary thyroid carcinoma: a meta-analysis and systematic review [0.03%]
甲状腺乳头状癌临床病理特征与BRAF V600E突变关系的系统综述和meta分析
Tao Fu,Jiahao Chen,Xiaxia Jin et al.
Tao Fu et al.
Background: The association between BRAF V600E mutation and clinicopathological features of papillary thyroid carcinoma (PTC) remains controversial. This study aimed to explore its prognostic value via meta-analysis. ...
The initial therapeutic response in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab contributes to the change of liver function during treatment: A multicenter analysis [0.03%]
阿特朱单抗联合贝伐珠单抗治疗不可切除的肝细胞癌患者的初始疗效与治疗期间肝功能变化相关：多中心分析
Takanori Suzuki,Ryo Sato,Kentaro Matsuura et al.
Takanori Suzuki et al.
Background: Therapeutic response in patients with unresectable hepatocellular carcinoma (HCC) receiving multikinase inhibitors is associated with changes in liver function. However, limited data are available for patients...